Clinical Research Directory
Browse clinical research sites, groups, and studies.
Iceland Screens, Treats or Prevents Multiple Myeloma
Sponsor: University of Iceland
Summary
This study will assess the benefits and harms of screening for monoclonal gammopathy of undetermined significance (MGUS). The overall and disease-specific mortality will be compared between screened and not screened participants. All individuals registered as inhabitants in Iceland and born in 1975 or earlier have been invited to participate. The hypothesis is that an early detection of multiple myeloma (MM), through follow-up of MGUS, will improve overall survival and decrease complications associated with diagnosis and treatment of MM.
Key Details
Gender
All
Age Range
40 Years - Any
Study Type
INTERVENTIONAL
Enrollment
80761
Start Date
2016-09-01
Completion Date
2026-09-01
Last Updated
2025-09-30
Healthy Volunteers
Yes
Interventions
Clinical follow-up 1
Participants receive routine care outside the bounds of the trial. No further work-up.
Mental Health and Quality of Life questionnaire
Participants receive a Mental Health and Quality of Life questionnaire that will be answered electronically on the study website (www.blodskimun.is)
Standard follow-up or treatment.
Participants previously diagnosed as having MGUS or participants that have multiple myeloma or other lymphoproliferative diseases will receive standard clinical follow-up and treatment.
Clinical follow-up 2
Standard clinical follow-up according to International Myeloma Working Group (IMWG) guidelines.
Clinical follow-up 3
Intensive clinical follow-up with regular clinical assessment, laboratory testing and radiology imaging.
Clinical follow-up control
Control clinical visit
Locations (1)
University of Iceland
Reykjavik, Iceland